Pharmosa Biopharm (ROCO:6875) Other Current Payables: NT$72.58 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6875 Pharmosa Biopharm Inc ROCO:6875
11 GF Score
Price NT$35.30
! 1 Warning Sign
View Full Analysis

What is Pharmosa Biopharm Other Current Payables?

Pharmosa Biopharm ROCO:6875 +0.43% 11 Other Current Payables is NT$72.58 Mil as of Dec. 2025. GuruFocus rates ROCO:6875 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Pharmosa Biopharm's Other Current Payables for the quarter that ended in Dec. 2025 was NT$72.58 Mil.

Pharmosa Biopharm's quarterly Other Current Payables declined from Jun. 2025 (NT$54.55 Mil) to Sep. 2025 (NT$52.37 Mil) but then increased from Sep. 2025 (NT$52.37 Mil) to Dec. 2025 (NT$72.58 Mil).

Pharmosa Biopharm's annual Other Current Payables increased from Dec. 2023 (NT$50.13 Mil) to Dec. 2024 (NT$90.39 Mil) but then declined from Dec. 2024 (NT$90.39 Mil) to Dec. 2025 (NT$72.58 Mil).

Pharmosa Biopharm Other Current Payables Related Terms

Pharmosa Biopharm Other Current Payables Historical Data

* Premium members only.

The historical data trend for Pharmosa Biopharm's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmosa Biopharm Other Current Payables Chart

Pharmosa Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial 17.34 16.33 50.13 90.39 72.58

Pharmosa Biopharm Quarterly Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 90.39 74.38 54.55 52.37 72.58
ROCO:6875
11GF Score
Pharmosa Biopharm Inc ROCO:6875
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmosa Biopharm Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of NT$72.58 Mil mean?
Pharmosa Biopharm (ROCO:6875) has a Other Current Payables of NT$72.58 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Pharmosa Biopharm and its competitors.
Is Pharmosa Biopharm's Other Current Payables too high?
Pharmosa Biopharm's current Other Current Payables is NT$72.58 Mil. Overall, Pharmosa Biopharm has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Pharmosa Biopharm's Other Current Payables compare to VRTX and REGN?
Pharmosa Biopharm's Other Current Payables of NT$72.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Pharmosa Biopharm and its competitors. Pharmosa Biopharm's current Other Current Payables is NT$72.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmosa Biopharm stock overvalued right now?
Pharmosa Biopharm (ROCO:6875) has a current Other Current Payables of NT$72.58 Mil. The current Other Current Payables is NT$72.58 Mil. Pharmosa Biopharm's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Pharmosa Biopharm (ROCO:6875), the current Other Current Payables is NT$72.58 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharmosa Biopharm Business Description

Address No. 508, Sec. 7, Zhongxiao E. Road, 11th Floor / 11th Floor-1, Nangang District, Taipei, TWN
Pharmosa Biopharm Inc is a world-class biotechnology company. The Company's principal business activities comprise the development and commercialization of inventive biopharmaceutical drugs. Its product portfolio includes sustained-release dosage forms and drug-device combination products intended for home based therapies.
11GF Score

Get the complete analysis for ROCO:6875

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$35.30
Price